Last updated: July 23, 2026
American Regent, Inc. v. Somerset Therapeutics, LLC is a 2024 federal Hatch-Waxman patent case filed in the District of New Jersey (case no. 1:24-cv-00248). The publicly available docket for this matter is not sufficient to produce a complete, accurate litigation summary and merits analysis of the asserted patents, claims, defenses, procedural posture, and any settlement or injunction outcomes.
What patents are asserted in American Regent v. Somerset Therapeutics (1:24-cv-00248)?
Answer: The asserted patents and claims cannot be identified from the information available in this record.
Which Orange Book product is at issue in the American Regent v. Somerset case?
Answer: The specific FDA-listed drug product tied to the asserted patents cannot be identified from the information available in this record.
What infringement theories are typically pleaded in this district for Hatch-Waxman ANDA actions?
Answer: The infringement theories cannot be confirmed for this case from the information available in this record.
What is the procedural posture in American Regent, Inc. v. Somerset Therapeutics, LLC (1:24-cv-00248)?
Answer: The case’s stage (e.g., motions to dismiss, claim construction, preliminary injunction, PTAB stay, summary judgment trial setting) cannot be confirmed from the information available in this record.
Has there been a preliminary injunction motion or hearing?
Answer: Not determinable from the information available in this record.
Have any claim construction rulings issued?
Answer: Not determinable from the information available in this record.
Has the case been stayed pending PTAB IPRs or related proceedings?
Answer: Not determinable from the information available in this record.
What filings and deadlines matter most in Hatch-Waxman cases like 1:24-cv-00248?
Answer: Key deadlines (answer date, scheduling order milestones, expert reports, dispositive motions, trial date) cannot be stated for this case from the information available in this record.
What does the docket say about motion practice?
Answer: Not determinable from the information available in this record.
What do the latest docket entries indicate about settlement likelihood?
Answer: Not determinable from the information available in this record.
How strong is American Regent’s patent estate in this dispute?
Answer: The strength of the patent estate cannot be analyzed because the asserted patent numbers, legal bases, and claim scope are not provided in the information available in this record.
Are method-of-use, formulation, or device/manufacturing patents implicated?
Answer: Not determinable from the information available in this record.
Are there known prior validity challenges or noninfringement arguments?
Answer: Not determinable from the information available in this record.
What Paragraph IV landscape surrounds American Regent v. Somerset (1:24-cv-00248)?
Answer: The presence of a Paragraph IV certification, the type of ANDA/BLA pathway, and the specific Orange Book listings cannot be determined from the information available in this record.
Which filing type is involved (ANDA vs. 505(b)(2))?
Answer: Not determinable from the information available in this record.
Which certification type was used for the challenged FDA submission?
Answer: Not determinable from the information available in this record.
What settlement terms or injunction outcomes exist for this case?
Answer: Settlement terms and any injunction or consent judgment cannot be stated from the information available in this record.
Has there been a stipulated dismissal without prejudice or with prejudice?
Answer: Not determinable from the information available in this record.
Did the court issue any patent infringement findings or permanent injunction?
Answer: Not determinable from the information available in this record.
What regulatory timeline risks exist for Somerset’s generic entry?
Answer: Regulatory entry risk cannot be quantified without knowing the product, FDA approval status, and patent-expiration/exclusivity timing tied to the asserted patents.
Could FDA approval be blocked by unexpired patents or exclusivity?
Answer: Not determinable from the information available in this record.
Does the case include any “launch-at-risk” exposure language?
Answer: Not determinable from the information available in this record.
Key Takeaways
- The case is docketed as American Regent, Inc. v. Somerset Therapeutics, LLC, 1:24-cv-00248 in the District of New Jersey.
- A complete litigation summary and technical merits analysis cannot be produced from the available record because asserted patents, product identity, pleaded claims, and procedural milestones are not provided.
FAQs
-
Who is the plaintiff and what is the docket number for American Regent v. Somerset Therapeutics?
American Regent, Inc.; 1:24-cv-00248.
-
Where is the litigation pending?
District of New Jersey.
-
Is this a Hatch-Waxman patent infringement case?
The case is associated with FDA patent litigation under Hatch-Waxman, but the specific submission type cannot be confirmed from the available record.
-
What is the impact on potential generic entry for Somerset?
Cannot be assessed without the product, Orange Book listings, and asserted patents.
-
Has the court issued a decision on preliminary relief?
Not determinable from the available record.
References (APA)
- U.S. District Court for the District of New Jersey. (2024). American Regent, Inc. v. Somerset Therapeutics, LLC (Case No. 1:24-cv-00248).
